ProCE Banner Activity

PRODIGE 24/CCTG PA.6: Phase III Trial of Adjuvant mFOLFIRINOX vs Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma

Slideset Download
Conference Coverage
A modified FOLFIRINOX regimen was superior to gemcitabine after resection of pancreatic cancer, with significantly prolonged disease-free, metastasis-free, and overall survivals.

Released: June 12, 2018

Expiration: June 11, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen